NeOnc Technologies Holdings, Inc.
NTHIHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, NeOnc Technologies Holdings, Inc. (NTHI) is listed under Biotechnology. The company carries a $94.2M market cap, placing it firmly in the micro-cap category. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers.
Market Cap
$94.2M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-3.00
EPS (TTM)
$-2.13
EPS (Fwd)
$-1.09
ROE
—
ROA
-635.0%
Cash
$2.0M
Total Debt
$328,217
Free CF
$5.4M
52W Change
-60.3%
Annual Financials
Cash vs Debt
Where NTHI stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, NTHI finished 39.96% below its 150-day moving average ($4.53) and 52.70% below its 200-day moving average ($5.75). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NTHI overbought or oversold?
At the October 20, 2026 close, NTHI's RSI(14) was 33.7, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $2.0M in cash comfortably exceeding the $328K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $5.4M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Revenue has grown from $20K (2022) to $40K (2025), reflecting a 100% increase over the period.
With cash comfortably exceeding debt, NTHI has financial flexibility that may help navigate uncertain periods. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for NeOnc Technologies Holdings, Inc. and its sector.